Answers are grounded in this paper and cite their sources.
Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).
No takes yet. Share an insight, caveat, or question.
Michael Tymianski (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: